---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-034904"
form_type: "8-K"
ticker: "MGTX"
cik: "0001735438"
company_name: "MeiraGTx Holdings plc"
filed_at: "2026-03-26T23:59:59+00:00"
generated_at: "2026-05-15T08:51:46.672599+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# MeiraGTx: FDA Breakthrough for xerostomia, FY2025 net loss $114.2M, $200M Hologen JV

## Summary
- FDA granted Breakthrough Therapy Designation for AAV2-hAQP1 for radiation-induced xerostomia; RMAT also granted.
- Strategic JV with Hologen: $200M upfront, $230M additional funding for AAV-GAD, MeiraGTx holds 30% ownership.
- Collaboration with Lilly: $75M upfront, >$400M milestones for AAV-AIPL1 and other ocular assets.
- FY2025 net loss $114.2M ($1.42/share) vs $147.8M ($2.12/share) in FY2024; cash $68.2M.
- Debt amendment: maturity extended to May 2027, $25M redemption by June 30, 2026, warrant price reduced to $8.00.

## SEC filing metadata
- accession: 0001104659-26-034904
- form_type: 8-K
- ticker: MGTX
- cik: 0001735438
- company_name: MeiraGTx Holdings plc
- filed_at: 2026-03-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.02, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1735438/000110465926034904/0001104659-26-034904-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1735438/000110465926034904/mgtx-20260325x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-034904
- JSON: https://secwatch.observer/filing/0001104659-26-034904.json
- Plain text: https://secwatch.observer/filing/0001104659-26-034904.txt

## Source-grounded claims
- claim_id: 6c5c72a88e4014c280d6dbcd2871611891c89d3d
  claim: MeiraGTx Holdings plc amended senior notes with Perceptive Credit Holdings III, LP maturing May 2, 2027.
  evidence_excerpt: Under the Amendments, the Maturity Date (as defined under the Notes Purchase Agreement) has been extended from August 2, 2026 to May 2, 2027 and the Company has agreed to redeem a portion of the outstanding principal amount of the Notes (as defined under the Notes Purchase Agreement) equal to $25,000,000 on or before June 30, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1735438/000110465926034904/0001104659-26-034904-index.htm
- claim_id: 4c18a95bbce82a76d6e5530e11417ccf55976b26
  claim: MeiraGTx Holdings plc reported financial results for the year ended December 31, 2025.
  evidence_excerpt: On March 26, 2026, the Company issued a press release announcing its financial results for the year ended December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1735438/000110465926034904/0001104659-26-034904-index.htm
- claim_id: bd0f4b66505151b0e8f3bc94b616e80b26662f3c
  claim: MeiraGTx Holdings plc amended Amendment No. 4 to Amended and Restated Notes Purchase Agreement and Amendment No. 1 to Warrant Certificates with Perceptive Credit Holdings III, LP valued at Extended Maturity Date from August 2, 2026 to May 2, 2027; agreed to redeem $25,000,000 principal on (effective 2026-03-25).
  evidence_excerpt: Item 1.01. Entry Into a Material Definitive Agreement. On March 25, 2026, MeiraGTx Holdings plc (the “Company”), as issuer, and its wholly-owned subsidiaries MeiraGTx UK II Limited, a company incorporated in England and Wales (“MeiraGTx UK II”), and MeiraGTx Ireland DAC, a designated activity company limited by shares incorporated in Ireland (“MeiraGTx Ireland,” and together with MeiraGTx UK II, the “Subsidiary Guarantors”), the noteholders and other parties from time to time party to the Notes Purchase Agreement (as defined below), and Perceptive Credit Holdings III, LP, as administrative agent and noteholder under the Notes Purchase Agreement (“Perceptive”), entered into Amendment No. 4 to Amended and Restated Notes Purchase Agreement and Amendment No. 1 to Warrant Certificates (the “Amendments”). The Amendments amend (A) the Amended and Restated Notes Purchase Agreement and Guaranty, dated December 19, 2022, between the Company, the Subsidiary Guarantors, the noteholders and oth
  evidence_url: https://www.sec.gov/Archives/edgar/data/1735438/000110465926034904/0001104659-26-034904-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.